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Abstract
Background: The intestinal microbiota influences metabolic, nutritional, and immunologic processes and has been
associated with a broad range of adverse health outcomes including asthma, obesity and Type 2 diabetes. Early life
exposures may alter the course of gut microbial colonization leading to differences in metabolic and immune
regulation throughout life. Although approximately 50 % of low-risk full-term infants born in Canada are exposed to
intrapartum antibiotics, little is known about the influence of this common prophylactic treatment on the developing
neonatal intestinal microbiota. The purpose of this study is to describe the intestinal microbiome over the first 3 years
of life among healthy, breastfed infants born to women with low-risk pregnancies at full term gestation and to
determine if at 1 year of age, the intestinal microbiome of infants exposed to intrapartum antibiotics differs in type and
quantity from the infants that are not exposed.
Methods: A prospectively followed cohort of 240 mother-infant pairs will be formed by enrolling eligible pregnant
women from midwifery practices in the City of Hamilton and surrounding area in Ontario, Canada. Participants will be
followed until the age of 3 years. Women are eligible to participate in the study if they are considered to be low-risk,
planning a vaginal birth and able to communicate in English. Women are excluded if they have a multiple pregnancy
or a preterm birth. Study questionnaires are completed, anthropometric measures are taken and biological samples are
acquired including eight infant stool samples between 3 days and 3 years of age.
Discussion: Our experience to date indicates that midwifery practices and clients are keen to participate in this
research. The midwifery client population is likely to have high rates of breastfeeding and low rates of intervention,
allowing us to examine the comparative development of the microbiome in a relatively healthy and homogenous
population. Results from this study will make an important contribution to the growing understanding of the patterns
of intestinal microbiome colonization in the early years of life and may have implications for best practices to support
the establishment of the microbiome at birth.
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Background
The intestinal microbiota is essential to metabolic, nutri-
tional and immunologic processes. The microbiome of
healthy adults varies significantly between individuals.
Differences in diversity or relative abundance of mi-
crobes has been associated with a broad range of adverse
health outcomes including: obesity, inflammatory bowel
disease, atopic disease, Type 2 diabetes, [1] multiple
sclerosis, [2] mental health or behaviour disorders, in-
cluding autism [3] and alcoholism [4]. The adult micro-
biota can be transiently altered by diet, infection and
antibiotic use, but in most individuals it reverts to the
composition observed before the perturbation [5–8].
In the newborn infant, following birth, colonisation of
the gut typically proceeds rapidly in the first hours and
days following initial exposure to maternal vaginal and
rectal microbiota and subsequently to maternal skin and
breast milk [9, 10]. Compared to adults, the infant micro-
biome is quite unstable, has greater inter- and intra-
individual variation, has a lower number of species and
has a higher proportion of Bifidobacterium [11]. Microbial
communities in the young child stabilize over time and
begin to resemble those in adults between 1 and 3 years of
age [12]. Factors such as the timing of weaning from
breast milk as well as the type and timing of the introduc-
tion of solid foods may contribute to this process, [13, 14]
but require further exploration. Membership of microbial
communities and colonization patterns has been shown to
differ by mode of birth. Caesarean section and exposure
of the newborn to antibiotics following birth cause devi-
ation from normal colonization patterns with disturbances
in and poor diversity of intestinal microbiota and these
differences have been shown to persist for up to 1 year
[15–18]. Caesarean section has been associated with a
number of long-term health outcomes and the gut micro-
biome has been implicated in the biological pathway [19,
20]. Thus, early exposure to the appropriate colonizing or-
ganisms is potentially critical to long-term health.
As many as 50 % of low-risk, full term infants born in
Canada are exposed to intrapartum antibiotic prophylaxis
(IAP); about 30 % because of prophylactic management
for Group B Streptococcus (GBS) [21] and the remainder
due to antibiotic coverage used for Caesarean birth. IAP
has the potential to impact early development of neonatal
intestinal microbiota, first because of the changed mater-
nal vaginal and rectal microbiota to which the neonate is
exposed during birth, and secondly due to the direct
exposure of the fetus to the antibiotic. Therefore, the
primary objective of our study is to determine if infants
born to women who receive IAP for GBS or a similar
regimen have intestinal microbiota at 1 year that differs
significantly in type and quantity from those not ex-
posed to IAP (Fig. 1).
Methods/Design
Study design and setting
A prospectively followed cohort of 240 mother-infant
pairs will be formed by enrolling eligible pregnant women
Fig. 1 Baby & Mi Study Framework. The cohort of women-infant dyads will be classified as either being exposed to intrapartum antibiotics for
Group B Streptococcus prophylaxis or unexposed. We will also collect information about other factors hypothesized to impact the intestinal micro-
biota at birth and during infancy/early childhood. The primary outcome is the intestinal microbiota at 1 year. Secondary outcomes include intes-
tinal microbiota, adiposity and markers of gut and systemic inflammation at 3 years. The hypothesized relationships between these outcomes is
shown using arrows
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from midwifery practices in the City of Hamilton and sur-
rounding area in Ontario, Canada. A pilot cohort (83
mother-infant pairs) was enrolled between July 1st 2012
and December 31st 2013. Recruitment for the second
phase of the study began October 1st 2014 and is ongoing.
Participants will be followed until the age of 3 years. The
study was approved by the joint Hamilton Health Sciences
- McMaster University Research Ethics Board and by Re-
search Ethics Boards at all participating healthcare
organizations.
Study population
Women are eligible to participate in the study if they are
considered to be low-risk (defined as being under the
care of a midwife), planning a vaginal birth and able to
communicate in English in order to provide signed in-
formed consent. Women are excluded from the study if
they have a known multiple pregnancy or a preterm
birth (before 37 completed weeks gestation). Women
who are enrolled prior to 37 completed weeks gestation
are contacted by telephone after 37 completed weeks to
reassess their eligibility.
Recruitment
The Baby & Mi study is advertised through pamphlets
and posters in the waiting areas at eight participating
midwifery practices and on social media. The midwives
and administrative staff are asked to inform their preg-
nant clients about the study. ‘Consent to Contact’ forms
are completed by mothers interested in hearing more
about the study and research personnel then contact
them by telephone or email. Study visits are arranged
with women who agree to participate.
Data collection
After providing informed consent, women are asked
to complete a baseline questionnaire that collects in-
formation about their pregnancy and family medical
history. Women enrolled at a gestational age less than
37 completed weeks are contacted by telephone
within 3 weeks of their estimated due date to reassess
time-dependent characteristics such as smoking status
and medication use during pregnancy. Case report
forms are available in Additional file 1.
Data about the pregnancy and birth are recorded
onto paper case report forms from antenatal forms,
the birth record and mother and infant charts by the
midwives. On day 3, day 10 and 6 weeks postpartum
participants are instructed to complete follow up
questionnaires and to place a diaper containing stool
in a labeled study bag and store the sample frozen in
their household freezer until their study visit when the
baby is 12 weeks of age. The women are reminded to
complete these tasks on the appropriate days by research
personnel through email or text message. In order to fa-
cilitate recall throughout the follow up period, mothers
are given a study diary that provides them with a place to
record events such as infections, medications and sleep
disturbances.
Participants are asked to attend follow up visits at
McMaster University Medical Centre at 12 weeks, 5 months,
1 year, 2 years and 3 years of age for stool sample delivery,
follow up data collection and measurements of infant
growth. Participants of the pilot study were also asked
to attend a follow up visit at 6 weeks postpartum.
Women are contacted between study visits to complete
questionnaires online or by telephone. A summary of
the data collection time points can be found in Table 1.
Table 1 Data Collection Timeline
Timepoint Data collection
Baseline Self-completed Questionnaire
36 to 37 weeks’ gestation Telephone questionnaire
Birth Midwife-completed questionnaire
Day 3 Self-completed Questionnaire Stool sample
Day 10 Self-completed Questionnaire Stool sample
6 weeks Self-completed Questionnaire Stool sample
12 weeks Study visit Self-completed Questionnaire Stool sample Anthropometric measurements PEA POD
4 months Telephone questionnaire
5 months Study visit Self-completed Questionnaire Stool sample Anthropometric measurements PEA POD
6 to 10 months Telephone questionnaires
1 year Study visit Self-completed Questionnaire Stool sample Anthropometric measurements
2 years Study visit Self-completed Questionnaire Stool sample Anthropometric measurements
3 years Study visit Self-completed Questionnaire Stool sample Anthropometric measurements DXA Blood draw
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Exposure assessment
Infants born to women who are administered prophylac-
tic antibiotic treatment for GBS or a similar regimen in
labour will be classified as IAP exposed. The unexposed
group includes infants born to women who are not ex-
posed to IAP. Women received IAP under the recommen-
dations of their care providers according to standard care
practices. Information about intrapartum antibiotic use is
collected from the birth record including indication, dose,
frequency and time to delivery from first dose.
Outcome assessment
The primary outcome is the type and abundance of spe-
cies present in the intestinal microbiota at 1 year of age,
which will be determined through bacterial diversity ana-
lysis and microbiota profiling of stool specimens This
comparison will also be made using stool samples col-
lected at day 3 and 10, 6 and 12 weeks, 5 months, 2 and
3 years of age.
Gut microbiome measurement
DNA extraction from stool is carried out using a previ-
ously described protocol that enhances DNA recovery
from microbial communities [22, 23] with modifications
to increase quantitative recovery of bacteria across differ-
ent taxa [24]. Upon delivery to the laboratory, stool sam-
ples are thawed and DNA is extracted. Approximately
100 mg of stool is sampled from each diaper. Where the
stool is fully absorbed into the diaper, a 1 cm by 1 cm
square of diaper is cut using sterile scissors and used for
DNA extraction. Bacterial community profiling of the 16S
rRNA gene is carried out using paired end reads of the V3
region using barcoded Illumina sequencing as described
previously [25]. Sample preparation and 250 paired-end
sequencing is carried out on a MiSeq Illumina sequencer
as per manufacturer’s instructions. This provides approxi-
mately 50,000–100,000 reads per sample that is processed
by an in-house bioinformatics pipeline [24] and the output
includes clustered sequences in operational taxonomic
units (OTUs) and taxonomic assignments as described
previously [26, 27].
Growth is monitored at each follow-up visit using stand-
ard approaches for the measurements of length, weight (in-
cluding weight to length ratio and peak weight velocity),
skinfold thickness (tricep, subscapular, bicep and suprai-
liac), head and hip circumference. The rate of fat accretion
will be determined using measurements of body com-
position at 6 weeks (pilot participants only), 12 weeks,
5 months and 3 years. At 6 weeks, 12 weeks and
5 months of age an air displacement plethysmography
system (PEA POD) is used to measure percent fat. At
3 years of age body composition is measured using
dual-energy X-ray absorptiometry (DXA).
Atopic disease is assessed during study visits and tele-
phone contacts by asking mothers if they suspect or have
been told by a physician that their child has eczema,
asthma, reactive airway disease or allergies. Symptoms of
eczema are also assessed using the Sampson Oranje cri-
teria for eczema [28] and the core questionnaire for ec-
zema that was developed by the International Study of
Asthma and Allergies in Childhood [29]. Sleep patterns
are reported at each contact using questions from the
Brief Index Sleep Questionnaire [30]. Symptomatic gas-
troesophageal reflux is evaluated at 6 weeks, 12 weeks,
5 months and 1 year using the Infant Gastroesophageal
Reflux Questionnaire Revised [31]. Gastrointestinal prob-
lems are measured at 30 months using the PedsQL-
Gastrointestinal Symptoms Scale [32]. Measures of
cardiometabolic health and systemic inflammation will be
made using fasting blood collected from each participant
at 3 years of age. This will include lipids, glucose and in-
flammatory markers. Fecal calprotectin will be measured
at 3 years of age as a marker for gut inflammation. Child
behaviour and temperament will be measured using the
Strengths and Difficulties [33] and the Children’s Behav-
iour Very Short Form questionnaires [34].
Covariate assessment
Additional information is collected to describe the study
population. Several variables will be assessed as confounders
or effect modifiers of the relationship between IAP exposure
and intestinal microbiota colonisation and secondary
outcomes. Covariates that are collected at baseline include:
maternal age, maternal pre-pregnancy weight, maternal
and household smoking status, medications taken during
pregnancy and first degree relative history of atopic disease,
obesity, allergies or heart disease. Information about the
pregnancy and birth are collected from birth records and
charts including: GBS screening results, mode of delivery,
place of birth (home or hospital), birth weight, length at
birth, sex of the newborn, Apgar scores, maternal and in-
fant antibiotic use prior to hospital discharge, intensive
care unit admission and time from birth until discharge or
the midwife leaving (homebirth). At follow up visits and
through telephone contacts, parents are asked about time-
varying covariates such as maternal and child exposure to
antibiotics or antifungals, other medication or health
product use, vaccine history, travel history, pets, daycare,
exposure to tobacco smoke and changes in feeding
(breast, formula or combination) including the addition
of solid food.
Sample size
Developing a sample size for studies in which the micro-
biota is the primary outcome is challenging. To date, most
studies investigating the infant microbiome have included
less than 100 subjects. To assess the feasibility of our
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study design, a sample size of 80 mother-infant pairs was
selected. Recruitment and the collection of stool and
data was found to be feasible, and attrition was low
(6 %). Therefore we determined that enrolling 160
mother-infant pairs in Phase 2, for a total sample size
of 240, was achievable.
Statistical analyses
We will use a diagram to summarize the patient flow in
the study. Demographic and prognostic baseline charac-
teristics will be reported as mean (standard deviation)
for continuous variables and count (percent) for categor-
ical variables. We will use regression analysis to analyze
data for all clinical outcomes with intrapartum exposure
to antibiotics as an independent variable after adjusting
for confounders. Clinically important covariates will be
investigated as potential confounders where appropriate
for each outcome. The results will be expressed as odds
ratio [OR] (for logistic regression for binary outcomes)
or coefficient (for linear regression for continuous out-
comes), corresponding standard error, 95 % confidence
intervals and associated p-values. P-values will be re-
ported to three decimal places with p-values less than
0.001 reported as p < 0.001. For all tests, we will use
alpha = 0.05 level of significance. Assessment of model
assumptions for regression analyses will be done by
examining the residuals.
There is likely to be missing data that will likely in-
crease with duration of the follow-up. We will use mul-
tiple imputation [35] to handle missing data. We will use
generalized estimating equations (GEE) [36] to account
for possible serial correlation of measurements within a
participant overtime. Unlike ordinary regression analysis,
GEE allows accounting for the possible correlation of
outcomes for participants over time. Lastly, we will use
propensity score methods to address the differential pro-
pensity for infant antibiotic exposure. All analyses will
be performed using R or SPSS statistical software.
To understand the influence of IAP on the infant gut
microbiota, we will analyze the microbial communities
using culture-independent microbiota profiling methods.
Microbiome analysis will include α-diversity metrics for
each sample and β-diversity measures (Bray-Curtis) and
other statistical analysis in R [37]. Association of microbial
community differences with sample groups will be assessed
with permutational multivariate analysis of variance using
Bray-Curtis dissimlarities (with vegan package in R) [38].
Association of taxon abundance with sample groups will be
assessed with a generalized linear mixed model with age
and intrapartum exposure as fixed effects and individual
child as a random effect using the lme4 package in R [39].
Functional properties of the microbiota will be inferred
using PICRUSt (Phylogenetic Investigation of Communities
by Reconstruction of Unobserved States) [40].
Discussion
Feasibility
We enrolled 32 % of women who completed a ‘Consent
to Contact’ form during the recruitment phase of our
pilot study. The rates of follow-up and of data comple-
tion have been excellent. Of the first 83 participants re-
cruited, one participant became ineligible prior to delivery
(high risk pregnancy identified). Two participants have
withdrawn; one prior to delivery and one at 12 weeks
postpartum. Two participants were lost to follow up,
resulting in 78 (94 %) participants remaining in the pilot
cohort. In the pilot cohort, 94 % of follow up visits up to
and including the 1-year visit were attended.
Strengths & limitations
We are developing a cohort of mother-infant pairs de-
rived from the midwifery client population, providing us
with the opportunity to examine a healthy pregnant and
newborn population with low intervention rates and high
breast-feeding rates. The homogeneity of this population
may allow us to better examine relationships between the
microbiome and exposures of interest. The midwifery popu-
lation also gives us the opportunity for novel observations
including place of birth (home and hospital) as a potential
covariate. However, our selection of a low-risk cohort will
preclude evaluation of nutritional intake that does not in-
clude breastfeeding or of exposures that occur with higher
risk pregnancies or following preterm birth. Thus, our find-
ings will need to be verified in these populations.
The investigative team is inter-professional in nature,
has complementary areas of expertise, and includes na-
tional leaders in their respective fields. Our team provides
expertise in pediatrics, obstetrics, midwifery, biostatistics,
epidemiology, basic science including animal modeling,
and microbiology, and is well suited both to undertake
this research and to bring results back to the clinical prac-
tice arenas where the findings will be most relevant.
Implications
Our research will provide documentation of the develop-
ment of the gut microbiome in a population of healthy
full term infants born to low-risk women at full term
gestation. By comparing the outcomes of exposed and
unexposed infants we provide a first step in evaluating
potential unforeseen negative consequences later in life
of the current GBS clinical guidelines advocating IAP for
GBS colonized women. Our team will explore this com-
plex issue with examination of outcomes at both the
microbiological level by examining intestinal colonisa-
tion in the first 3 years of life and in exploring the influ-
ence on systemic inflammation, adiposity, atopic disease
and other outcomes of interest. Results from this study
will make an important contribution to the growing
body of knowledge and understanding of the patterns of
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intestinal microbiome establishment in the early years of
life and the impact of IAP on the development of intes-
tinal microbiota in newborns.
Additional file
Additional file 1: Case Report Forms. This file contains the case report
forms to be completed by participants and research staff from the time
of eligibility assessment and enrollment to the time of the 3 year study
visit. (PDF 1007 kb)
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